GMAB - Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

• Cancer immunotherapy developer Immatics ( NASDAQ: IMTX ) is up 17% in Tuesday afternoon trading on volume that is ( IMTX ) four times higher than the normal daily average.
• Average volume for the stock is 146,757. As of 230p ET, ~586K shares had traded hands.
• There is no news from Immatics ( IMTX ) or other catalyst that might explain the upswing.
• The company is focused on T-cell receptor T (TCR-T) cell therapies. Its most advanced candidate is in phase 1b, according to a recent corporate presentation .
• Immatics ( IMTX ) also has partnerships with Bristol-Myers Squibb ( BMY ), GlaxoSmithKline ( GSK ), and Genmab ( GMAB )
• Seeking Alpha's Quant Rating views Immatics ( IMTX ) as a buy with high grades for profitability and revision s.

For further details see: